GILD vs REGN: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

REGN has stronger fundamentals based on our AI analysis.

GILD
GILEAD SCIENCES, INC.
A
78%
Confidence
VS
REGN
REGENERON PHARMACEUTICALS, INC.
A
80%
Confidence

GILD vs REGN Fundamental Comparison

Metric GILD REGN
Revenue $7.0B $3.6B
Net Income $2.0B $727.2M
Net Margin 29.0% 20.2%
ROE 8.6% 2.3%
ROA 3.6% 1.8%
Current Ratio 1.97x 3.57x
Debt/Equity 0.94x 0.06x
EPS $1.61 $6.75

Green = Better metric | Red = Weaker metric

View Full GILD Analysis →
View Full REGN Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Top Rated Undervalued Growth Dividend

You Might Also Compare

GILD vs AAPL REGN vs MSFT GILD vs GOOGL REGN vs AMZN

GILD vs REGN: Frequently Asked Questions

Is GILD or REGN the better stock in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. GILD is graded A (78% confidence) while REGN is graded A (80% confidence). This is not investment advice.

How does GILD compare to REGN fundamentally?

GILEAD SCIENCES, INC. has ROE of 8.6% vs REGENERON PHARMACEUTICALS, INC.'s 2.3%. Net margins are 29.0% vs 20.2% respectively.

Which stock pays higher dividends, GILD or REGN?

GILD has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in GILD or REGN for long term?

For long-term investing, consider that GILD has a A grade with 78% confidence, while REGN has a A grade with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about GILD vs REGN?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GILD vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.